Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.37 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 11/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4899362 | 0.83 | MEN1 (0.42) | MEN1KMT2ANPC1LMNAGAA | |
| SCHEMBL4896111 | 0.81 | NPSR1 (0.41) | MEN1KMT2A | |
| SCHEMBL4895747 | 0.81 | BRD4 (0.41) | MEN1KMT2ALMNAGAA | |
| Hydrochloric Acid SCHEMBL4889333 | 0.79 | DPP4 (0.41) | MEN1KMT2ADPP4DPP8NPC1 | |
| SCHEMBL4897374 | 0.79 | PTGDR2 (0.41) | MEN1KMT2A | |
| SCHEMBL4891152 | 0.75 | PARK7 (0.36) | MEN1KMT2ANPC1POLBGAA | |
| SCHEMBL4899852 | 0.74 | ALDH1A1 (0.41) | MEN1KMT2ANPC1LMNAPOLB | |
| SCHEMBL4897077 | 0.73 | RIPK1 (0.38) | MEN1KMT2APOLBGAA | |
| SCHEMBL4897407 | 0.71 | CYP1A2 (0.39) | MEN1KMT2AGAA | |
| SCHEMBL4887310 | 0.69 | ADRA2A (0.37) | MEN1KMT2AGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009512-A1 | Tetrahydroquinolones and Aza-Analogues Thereof for Use as Dpp-IV Inhibitors in the Treatment of Diabetes | DPP4, DPP8, DPP3 | MEN1 2942/4885KMT2A 911/4885DPP4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.